Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Advanced Nonmelanoma Skin Cancer Disease State Roundtable

In this roundtable session focused on advanced nonmelanoma skin cancer, panelists Dr Todd Schlesinger, Dr Aaron Farberg, Dr Mark Kaufmann, and Dr Harrison Nguyen share their insights on the current advanced cutaneous squamous cell carcinoma (aCSCC) and advanced basal cell carcinoma (aBCC) disease state. These distinguished experts discuss their clinical approach to diagnosing and managing aCSCC and aBCC, highlight the current treatment landscape and how it is evolving, including recent clinical data on neoadjuvant immunotherapy, and offer their perspectives on the clinical challenges of managing aCSCC and aBCC.


Disease State Overview of Current Advanced Nonmelanoma Skin Cancers

Video 1 image

In this roundtable session, expert dermatologists discuss how to define types of advanced nonmelanoma skin cancers, specifically advanced cutaneous squamous cell carcinoma (aCSCC) and advanced basal cell carcinoma (aBCC). This discussion elaborates on the epidemiology and pathophysiology of these carcinomas, as well as risk factors and warning signs to be aware of. 


Clinical Approach to the Diagnosis & Management of aCSCC and aBCC

Video 2 image

In this roundtable session, expert dermatologists describe current diagnostic approaches and risk factors for disease progression in advanced cutaneous squamous cell carcinoma (aCSCC) and advanced basal cell carcinoma (aBCC). This discussion covers the latest guideline recommendations for treating patients with aCSCC and aBCC and highlights key takeaways from recent clinical data on therapies such as neoadjuvant therapies. 


Clinical Challenges and the Evolving Landscape of aCSCC and aBCC 

Video 3 image

In this roundtable session, expert dermatologists delve into the current unmet needs and clinical challenges in the management of advanced cutaneous squamous cell carcinoma (aCSCC) and advanced basal cell carcinoma (aBCC). This discussion examines the advancing treatment landscape of aCSCC and aBCC and how the expert dermatologists view the aCSCC and aBCC treatment landscapes changing in the future.  

Advertisement

Advertisement

Advertisement